PapersFlow Research Brief

Life Sciences · Biochemistry, Genetics and Molecular Biology

Protease and Inhibitor Mechanisms
Research Guide

What is Protease and Inhibitor Mechanisms?

Protease and inhibitor mechanisms refer to the biochemical processes by which matrix metalloproteinases (MMPs) degrade extracellular matrix components and the regulatory roles of tissue inhibitors of metalloproteinases (TIMPs) in controlling MMP activity during physiological and pathological conditions.

Matrix metalloproteinases (MMPs) hydrolyze extracellular matrix components and participate in embryogenesis, tissue remodeling, wound healing, angiogenesis, and diseases including cancer and atherosclerosis, as detailed in 70,028 papers on this topic. Tissue inhibitors of metalloproteinases (TIMPs) directly inhibit MMPs to balance proteolysis in normal and pathological states. These mechanisms regulate cell signaling, inflammation, and tumor progression through pericellular substrate processing.

Topic Hierarchy

100%
graph TD D["Life Sciences"] F["Biochemistry, Genetics and Molecular Biology"] S["Cancer Research"] T["Protease and Inhibitor Mechanisms"] D --> F F --> S S --> T style T fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan
70.0K
Papers
N/A
5yr Growth
1.9M
Total Citations

Research Sub-Topics

Why It Matters

MMPs contribute to cancer progression by remodeling the extracellular matrix, promoting angiogenesis and metastasis, as shown in "New functions for the matrix metalloproteinases in cancer progression" where Egeblad and Werb (2002) identified roles beyond matrix degradation in tumor microenvironments. In atherosclerosis, MMPs drive plaque instability, per Ross (1993) in "The pathogenesis of atherosclerosis: a perspective for the 1990s". TIMPs modulate these effects, offering therapeutic potential; for instance, imbalances lead to excessive tissue remodeling in arthritic diseases, highlighted by Visse and Nagase (2003) in "Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases", which notes MMPs' central role in over 20 disease contexts including atheroma.

Reading Guide

Where to Start

"Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases" by Visse and Nagase (2003) provides a foundational overview of MMP structures, TIMP inhibition mechanisms, and biological roles, making it ideal for beginners to grasp core concepts before advanced topics.

Key Papers Explained

Visse and Nagase (2003) in "Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases" establish MMP enzymology and TIMP regulation, which Sternlicht and Werb (2001) in "How Matrix Metalloproteinases Regulate Cell Behavior" extend to pericellular signaling mechanisms. Egeblad and Werb (2002) in "New functions for the matrix metalloproteinases in cancer progression" and Kessenbrock et al. (2010) in "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment" build on these by detailing cancer-specific roles, while Bonnans et al. (2014) in "Remodelling the extracellular matrix in development and disease" integrates developmental contexts.

Paper Timeline

100%
graph LR P0["The pathogenesis of atherosclero...
1993 · 10.6K cites"] P1["Tissue Plasminogen Activator for...
1995 · 11.6K cites"] P2["How Matrix Metalloproteinases Re...
2001 · 3.9K cites"] P3["New functions for the matrix met...
2002 · 6.0K cites"] P4["Matrix Metalloproteinases and Ti...
2003 · 4.5K cites"] P5["Matrix Metalloproteinases: Regul...
2010 · 4.9K cites"] P6["Remodelling the extracellular ma...
2014 · 4.1K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P1 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Studies continue to explore MMPs in tumor microenvironments and ECM remodeling, as in Kessenbrock et al. (2010) and Bonnans et al. (2014), with no recent preprints signaling steady progress in disease applications like cancer and atherosclerosis.

Papers at a Glance

Frequently Asked Questions

What are matrix metalloproteinases (MMPs)?

MMPs, also called matrixins, are a family of over 25 secreted and cell surface enzymes that hydrolyze extracellular matrix components. They play central roles in embryogenesis, normal tissue remodeling, wound healing, angiogenesis, and diseases such as cancer and atherosclerosis. Nagase and Woessner (1999) in "Matrix Metalloproteinases" emphasize their necessity for timely ECM breakdown in development and morphogenesis.

How do tissue inhibitors of metalloproteinases (TIMPs) function?

TIMPs directly inhibit MMPs by binding to their active sites, regulating proteolysis in physiological processes like tissue remodeling. Visse and Nagase (2003) in "Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases" describe this inhibition as essential for balancing MMP activity in wound healing and preventing pathological remodeling in diseases like arthr.

What roles do MMPs play in cancer progression?

MMPs regulate the tumor microenvironment by processing substrates that influence cell behavior, angiogenesis, and metastasis. Kessenbrock et al. (2010) in "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment" show MMPs control tumor progression through ECM remodeling and signaling. Egeblad and Werb (2002) in "New functions for the matrix metalloproteinases in cancer progression" detail non-matrix roles in inflammation and growth factor release.

How do MMPs regulate cell behavior?

MMPs process pericellular substrates including proteinases, inhibitors, clotting factors, and growth factors to modulate cell migration, proliferation, and signaling. Sternlicht and Werb (2001) in "How Matrix Metalloproteinases Regulate Cell Behavior" identify over 25 MMPs targeting chemotactic molecules and latent growth factors. This regulation occurs in development, tissue remodeling, and disease contexts.

What is the current state of research on protease inhibitors in disease?

Research encompasses 70,028 papers on MMPs and TIMPs, focusing on their roles in cancer, angiogenesis, and inflammation regulation. Key works like Bonnans et al. (2014) in "Remodelling the extracellular matrix in development and disease" link dysregulated MMP activity to pathological ECM changes. No recent preprints or news coverage indicate ongoing foundational studies without major shifts.

Open Research Questions

  • ? How do specific MMP-TIMP interactions differentially regulate angiogenesis versus metastasis in distinct tumor types?
  • ? What pericellular substrates beyond ECM components mediate MMP effects on inflammation and cell signaling?
  • ? Why do MMP inhibitors fail in clinical cancer trials despite preclinical success in blocking tumor progression?
  • ? How do MMPs contribute to extracellular matrix remodeling in atherosclerosis independently of inflammation?
  • ? Which novel MMP functions in development can be targeted to treat diseases like arthrosis without disrupting normal tissue homeostasis?

Research Protease and Inhibitor Mechanisms with AI

PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:

See how researchers in Life Sciences use PapersFlow

Field-specific workflows, example queries, and use cases.

Life Sciences Guide

Start Researching Protease and Inhibitor Mechanisms with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers